Pantoprazol Mylan (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazol Mylan, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Pantoprazol Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Mylan is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Erosive esophagitis: accelerates mucosal healing and reduces symptom recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours. - Prevention of NSA‑induced gastric ulcers: lowers the risk of ulcer formation in patients taking non‑steroidal anti‑inflammatory drugs. - Healing of peptic ulcer disease: supports ulcer resolution when used as part of combination therapy.

Pantoprazol Mylan may cause a range of adverse reactions. Most are mild and transient, but some require prompt medical attention.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: watery stools, often self‑limiting. - Nausea or vomiting: occasional gastrointestinal discomfort. - Abdominal pain or flatulence: mild cramping or gas. - Constipation: reduced bowel movements. - Dry mouth: sensation of oral dryness.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent diarrhoea with abdominal pain. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: signs of hepatic stress. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy with Pantoprazol Mylan, consider the following safety measures: - Assess renal function: dose adjustment may be required in severe impairment. - Review hepatic status: monitor liver enzymes in patients with liver disease. - Evaluate long‑term use: weigh benefits against potential risk of fractures and nutrient malabsorption. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Concomitant medications: check for interactions that may affect drug levels. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Mylan can affect the absorption or metabolism of several medicines. Monitoring and dose adjustments may be necessary.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): markedly reduced absorption. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Clopidogrel: reduced antiplatelet effect. - Warfarin: potential alteration of INR values. - Methotrexate: increased systemic exposure, especially in renal impairment. - Digoxin: modest increase in serum levels. - Oral contraceptives: possible decrease in efficacy.